{"id":"l-ornithine-l-aspartate-plus-latulose","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Flatulence"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L-ornithine-L-aspartate (LOLA) provides substrates for the urea cycle and glutamine synthesis, directly lowering blood ammonia concentrations. Lactulose acts as a non-absorbable disaccharide that lowers colonic pH, inhibits ammonia-producing bacteria, and increases fecal nitrogen excretion. Together, these agents synergistically reduce hyperammonemia and its neurological consequences.","oneSentence":"L-ornithine-L-aspartate reduces ammonia levels by promoting its conversion to urea and glutamine, while lactulose acidifies the colon to reduce ammonia-producing bacteria and increase fecal ammonia excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:26.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatic encephalopathy"},{"name":"Portal systemic encephalopathy"}]},"trialDetails":[{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":"Overt Hepatic Encephalopathy","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Levijon concentrate for infusion plus Duphalac"],"phase":"marketed","status":"active","brandName":"L-ornithine-L-aspartate plus latulose","genericName":"L-ornithine-L-aspartate plus latulose","companyName":"Qurratul Ain Jamil","companyId":"qurratul-ain-jamil","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-ornithine-L-aspartate reduces ammonia levels by promoting its conversion to urea and glutamine, while lactulose acidifies the colon to reduce ammonia-producing bacteria and increase fecal ammonia excretion. Used for Hepatic encephalopathy, Portal systemic encephalopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}